Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591
Source: Journal of Dermatological Treatment - Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
More News: Acne | Clinical Trials | Dermatitis | Dermatology | Eczema | Herpes | Japan Health | Skin | Study